Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.
Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S, Aigner M, Rothe T, Minopoulou I, Tur C, Knitza J, Kharboutli S, Kretschmann S, Vasova I, Spoerl S, Reimann H, Munoz L, Gerlach RG, Schäfer S, Grieshaber-Bouyer R, Korganow AS, Farge-Bancel D, Mougiakakos D, Bozec A, Winkler T, Krönke G, Mackensen A, Schett G. Müller F, et al. Among authors: kretschmann s. N Engl J Med. 2024 Feb 22;390(8):687-700. doi: 10.1056/NEJMoa2308917. N Engl J Med. 2024. PMID: 38381673
Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy.
Reimann H, Nguyen A, Sanborn JZ, Vaske CJ, Benz SC, Niazi K, Rabizadeh S, Spilman P, Mackensen A, Ruebner M, Hein A, Beckmann MW, van der Meijden ED, Bausenwein J, Kretschmann S, Griffioen M, Schlom J, Gulley JL, Lee KL, Hamilton DH, Soon-Shiong P, Fasching PA, Kremer AN. Reimann H, et al. Among authors: kretschmann s. J Immunother Cancer. 2021 Jun;9(6):e002605. doi: 10.1136/jitc-2021-002605. J Immunother Cancer. 2021. PMID: 34172517 Free PMC article.
Influence of DM-sensitivity on immunogenicity of MHC class II restricted antigens.
Bernhardt AL, Zeun J, Marecek M, Reimann H, Kretschmann S, Bausenwein J, van der Meijden ED, Karg MM, Haug T, Meintker L, Lutzny-Geier G, Mackensen A, Kremer AN. Bernhardt AL, et al. Among authors: kretschmann s. J Immunother Cancer. 2021 Jul;9(7):e002401. doi: 10.1136/jitc-2021-002401. J Immunother Cancer. 2021. PMID: 34266882 Free PMC article.
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus.
Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, Böltz S, Manger B, Mackensen A, Schett G. Mougiakakos D, et al. Among authors: kretschmann s. N Engl J Med. 2021 Aug 5;385(6):567-569. doi: 10.1056/NEJMc2107725. N Engl J Med. 2021. PMID: 34347960 No abstract available.
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, Simon D, Kleyer A, Munoz L, Kretschmann S, Kharboutli S, Gary R, Reimann H, Rösler W, Uderhardt S, Bang H, Herrmann M, Ekici AB, Buettner C, Habenicht KM, Winkler TH, Krönke G, Schett G. Mackensen A, et al. Among authors: kretschmann s. Nat Med. 2022 Oct;28(10):2124-2132. doi: 10.1038/s41591-022-02017-5. Epub 2022 Sep 15. Nat Med. 2022. PMID: 36109639
Successful Generation of CD19 Chimeric Antigen Receptor T Cells from Patients with Advanced Systemic Lupus Erythematosus.
Kretschmann S, Völkl S, Reimann H, Krönke G, Schett G, Achenbach S, Lutzny-Geier G, Müller F, Mougiakakos D, Dingfelder J, Flamann C, Hanssens L, Gary R, Mackensen A, Aigner M. Kretschmann S, et al. Transplant Cell Ther. 2023 Jan;29(1):27-33. doi: 10.1016/j.jtct.2022.10.004. Epub 2022 Oct 12. Transplant Cell Ther. 2023. PMID: 36241147 Free article.
Author Correction: Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, Simon D, Kleyer A, Munoz L, Kretschmann S, Kharboutli S, Gary R, Reimann H, Rösler W, Uderhardt S, Bang H, Herrmann M, Ekici AB, Buettner C, Habenicht KM, Winkler TH, Krönke G, Schett G. Mackensen A, et al. Among authors: kretschmann s. Nat Med. 2023 Nov;29(11):2956. doi: 10.1038/s41591-022-02091-9. Nat Med. 2023. PMID: 36329355 No abstract available.
CD19-targeted CAR T cells in refractory antisynthetase syndrome.
Müller F, Boeltz S, Knitza J, Aigner M, Völkl S, Kharboutli S, Reimann H, Taubmann J, Kretschmann S, Rösler W, Manger B, Wacker J, Mougiakakos D, Jabari S, Schröder R, Uder M, Roemer F, Krönke G, Mackensen A, Schett G. Müller F, et al. Among authors: kretschmann s. Lancet. 2023 Mar 11;401(10379):815-818. doi: 10.1016/S0140-6736(23)00023-5. Epub 2023 Feb 15. Lancet. 2023. PMID: 36930673 No abstract available.
Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells.
Bergmann C, Müller F, Distler JHW, Györfi AH, Völkl S, Aigner M, Kretschmann S, Reimann H, Harrer T, Bayerl N, Boeltz S, Wirsching A, Taubmann J, Rösler W, Spriewald B, Wacker J, Atzinger A, Uder M, Kuwert T, Mackensen A, Schett G. Bergmann C, et al. Among authors: kretschmann s. Ann Rheum Dis. 2023 Aug;82(8):1117-1120. doi: 10.1136/ard-2023-223952. Epub 2023 May 5. Ann Rheum Dis. 2023. PMID: 37147112 Free PMC article. No abstract available.
Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies.
Taubmann J, Knitza J, Müller F, Völkl S, Aigner M, Kleyer A, Gary R, Kretschmann S, Boeltz S, Atzinger A, Kuwert T, Roemer F, Uder M, Mackensen A, Schett G. Taubmann J, et al. Among authors: kretschmann s. Rheumatology (Oxford). 2024 Jan 4;63(1):e12-e14. doi: 10.1093/rheumatology/kead330. Rheumatology (Oxford). 2024. PMID: 37432378 Free PMC article. No abstract available.
17 results